By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Worldwide, cardiovascular disease is the leading cause of mortality and morbidity. Several subtypes of cardiovascular disease need innovative surgical and interventional diagnostic and therapeutic techniques, as well as extremely complex biomaterial-based devices.
Recognising and comprehending the complications of these devices, many of which are related to the biomaterials that comprise them, has resulted in iterative efforts to improve their performance and safety through biomaterials and device research and development, resulting in better patient care.
Prosthetic heart valves, coronary stents, endovascular grafts, and angioplasty balloon catheters save countless lives each year and dramatically improve the quality of life for millions of individuals.
Furthermore, due to the increased risk to patients, cardiovascular devices are subject to comprehensive evaluation and supervision by medical device regulators in the majority of big countries.
Implanted cardiovascular devices, for example, will soon be required to meet the more stringent criteria of the new EU medical device regulation (MDR) in the EU.Overcoming these and other challenges requires cardiovascular device manufacturers to have extensive technical knowledge as well as substantial regulatory experience.
These obstacles can be especially difficult for small and medium-sized enterprises, which make up the great bulk of medical device manufacturers. Cardiovascular medical devices, including the underlying pathophysiology of the conditions they are intended to treat, relevant biomaterials from which they are produced, and the most significant complications that must be avoided, minimized, or regulated.
It focuses on biomaterials and engineering design issues in cardiac valve prostheses, pacemakers and implantable cardioverter-defibrillators, implantable cardiac assist devices and artificial hearts, and various intracardiac devices, such as septal defect closure devices and left atrial occlusion devices, to treat cardiovascular disease in a minimally invasive manner.
The Canada Cardiovascular Medical Devices Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The TRAVELLER Portal Vein Access Series is the newest addition to Argon Medical Devices portal vein access product range. Argon Medical Devices is a prominent developer of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology.
The product line is intended to suit the unique requirements of clinicians who need to enter the portal vein via the liver during Transjugular Intrahepatic Portosystemic Shunt (TIPS) surgeries. TRAVELLER complements Argon’s well-known release of SCORPION, which also supports TIPS operations.
TRAVELLER is intended to increase component visibility and longevity, which are frequent TIPS process problems. When compared to other sets on the market, the TRAVELER set’s novel characteristics make it easier to access the portal vein. For starters, the metal cannula is extremely durable, and the shaping tool allows it to be curled to significant depths without jeopardizing component integrity.
Second, the puncture needle is longer and seems to be sharper, making it simpler to pierce through extremely fibrotic liver parenchyma and reach the portal vein even when the anatomy is substantially deformed.
